Current Cancer Therapy Reviews

World Cancer Day, 2020!

world-cancer-day--1200x630

Bentham Science publish Articles related to World Cancer Day in its SUBSCRIPTION BASED JOURNALS including:

Anti-Cancer Agents in Medicinal Chemistry

Clinical Cancer Drugs

Current Cancer Drug Targets

Current Cancer Therapy Reviews

Recent Patents on Anti-Cancer Drug Discovery

For Books, please find the link here consisting of all the relevant eBooks and AVAIL 30% DISCOUNT OFFER on related books!

Press Release | TWO BENTHAM SCIENCE JOURNALS INDEXED IN THE EMERGING SOURCES CITATION INDEX (ESCI)

News release date: November 22, 2018

The Emerging Sources Citation Index (ESCI), a new database within the Web of Science by Clarivate Analytics, has accepted to index two journals published by Bentham Science Publishers. The titles are:

Current Cancer Therapy Reviews
Current Rheumatology Reviews

The Emerging Sources Citation Index (ESCI) is a new index by Clarivate Analytics, extending the range of publications in Web of Science to include high-quality, peer-reviewed publications of regional importance and in emerging scientific fields. ESCI complements the highly selective indexes by providing earlier visibility for sources under evaluation as part of SCIE, SSCI, and AHCI’s rigorous journal selection process. Inclusion in ESCI provides greater discoverability which leads to increased citations.

For more details, please visit: https://benthamscience.com/press-releases/18112201/

ARTICLE BY DISEASE – Anal Carcinoma

ARTICLE BY DISEASE ON “ANAL CANCER”

Abstract:

Anal carcinoma accounts for less than 2% of all gastrointestinal malignancies. The incidence of anal cancer is increasing and may be associated with an increase in anal receptive intercourse or higher number of sexual partners. Such behaviors have also increased the risk of infection with both HIV and human papilloma virus (HPV). HPV appears to induce dysplasia in the anal mucosa, which is readily detectable and treatable. The strong association of HPV has even spurred research into primary prevention in high-risk patients. Models suggest that screening in the highest risk patients would not only confer a survival benefit but also be cost effective. While the overall prognosis is only a 55% survival at 5 years, survival for localized disease remains near 80%. Traditional staging by cross-sectional imaging may be giving way to endorectal ultrasound and sentinel node biopsy. The standard of care for anal canal carcinoma is now combined modality therapy (CMT) with chemoradiation therapy obtaining excellent oncologic results as well as organ preservation. Advances in intensity modulated radiation therapy (IMRT) and brachytherapy have significantly decreased toxicity. Surgery improves survival in patients with persistent or residual disease Within the next decade, anal cancer may emerge as a preventable form of cancer.

For more details, please visit: http://www.eurekaselect.com/node/69137/article

New Issue :: Current Cancer Therapy Reviews (Volume: 14, Issue: 2)

Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.

cctr

Articles from the journal Current Cancer Therapy Reviews Volume 14, Issue 2:

For details on the articles, please visit this link: https://bit.ly/2LXllXz

MOST ACCESSED ARTICLE – Papain Loaded Solid Lipid Nanoparticles for Colorectal Cancer Therapy – Current Cancer Therapy Reviews

Journal: Current Cancer Therapy Reviews

Author(s): Suriyakala P. Chandran, Kannika P. Nachinmuthu, Satheesh B. Natarajan*, Mohammad G. Inamdar, Masliza S.B.M. Shahimi

Graphical Abstract:

Abstract:

Background: Colorectal cancer (CRC) also known as bowl cancer is still one of the leading causes of cancer related mortality worldwide. Generally tumor cells are protecting themselves by fibrin coat and it is resistant to fibrinolytic degradation. Such a coated tumor appears as ‘self’ to the immune system, and thus is not detected as a tumor by the immune system (i.e. natural killer cells). Hence, a potent proteolytic enzyme has to propose/ identify to dissolve the protective fibrin layer, exposing the tumor cell surface to chemotherapy and immune attack. In this research papain was considered to be the potential proteolytic agent, can break down the fibrin coat of cancer cell wall and ultimately the cancer cells are exposed to immune attack and help against the cancer. Secondly, the cytotoxic compound(s) directly deliver to cancer site without harm to normal cells.

Methods: The attempt made to attain this objective, we were designed to fabricate the Papain loaded solid lipid nanoparticles (SLN) by melt dispersion-ultrasonication technique, and investigate the various formulation parameters. The papain loaded SLN was characterized by particle size analysis, zeta potential analysis, differential scanning calorimetry (DSC), Scanning electron microscopy (SEM), drug encapsulation efficiency, in vitro drug release, and in vitro cytotoxicity studies on HT-29 colorectal cancer cells.

Results: The successful outcome of this research was that, the cetyl alcohol based SLN of papain were successfully prepared by using melt dispersion- ultrasonication method with maximum encapsulation efficiency with desired particle size. The release profile of the produced SLN was investigated in phosphate buffer media, and it showed prolonged release during 24 h. The drug release behaviour from the SLNs exhibited a biphasic pattern with the burst release at the initial stage and sustained release subsequently. Future perspective of this research is that need to investigate the SLN for the lymphatic uptake to produce local action on metastatic colorectal cancer. In vitro cell viability for P-SLNs was tested on colorectal Adenocarcinoma HT-29 cells by MTT assay. The results revealed that the in vitro cell viability against different concentrations of papain was 99% and 31 % which were treated with 5µg/ml and 80µg/ml concentration respectively. The cell viability of HT-29 cells was decreased signicantly from 94 % to 17 % treated with P-SLN at 5 µg/ml and 80 µg/ml concentration respectively. Therefore, the papain loaded SLNs exhibits a better performance on getting lower cell viability (or) equivalent high cytotoxicity than that of pure papain. Therefore, the SLNs delivery system plays a significant role in enhancing the cytotoxic efficacy of papain enzyme against colorectal cancer cells.

Conclusion: In this research, we successfully formulated the P-SLN for the treatment of colorectal cancer therapy. We investigate the various formulation parameters, drug release profile and cytotoxic efficacy of P-SLN. Upon successful completion of this work, P-SLNs delivery system is predictable to produce enhanced cytotoxic efficacy against HT-29 colorectal cancer cells. The papain loaded SLNs can potentially be utilized as a drug delivery system for the treatment of colorectal cancer. In future, we will explore further to investigate the mechanism of anticancer activity and clinical investigation of P-SLN.

Read more here: http://www.eurekaselect.com/155999/article

NEW ISSUE ::: Current Cancer Therapy Reviews 14, ISSUE 1

Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.

cctr

Articles from the journal Recent Patents on Current Cancer Therapy Reviews Volume 14, Issue 1:

Meet Our Editorial Board Member
Preface
Editorial: The Role of Stereotactic Body Radiotherapy: A Review
SBRT for Liver Cancer
Stereotactic Body Radiotherapy (SBRT) in the Management of Clinically Localized Prostate Cancer: Where are We Now?
The Role of Stereotactic Body Radiation Therapy in Pancreatic Cancer
Role of Stereotactic Radiosurgery in the Management of Brain and Spine Metastases
Papain Loaded Solid Lipid Nanoparticles for Colorectal Cancer Therapy

For details on the articles, please visit this link: http://bit.ly/2FV0130

EDITOR’S CHOICE – Stereotactic Body Radiation Therapy in Head and Neck Squamous Cell Carcinoma – Current Cancer Therapy Reviews

Journal: Current Cancer Therapy Reviews

Author(s): Rashi Garg, Omar Mahmoud

Abstract:

Background: Stereotactic body radiotherapy (SBRT) or radiosurgery has emerged as a viable highly precise technique that delivers a hypofractionated radiotherapy regimen with a high biologic effective dose. In addition to patient convenience, this dose is thought to provide acceptable local control while keeping toxicity to a minimum due to the typical small target size. The aims of this paper are to review recent outcomes with the application of SBRT in the management of head and neck cancer.

Methods: Research and online content related to head and neck cancer SBRT were reviewed focusing on dose fractionation schedules, incorporation of systemic therapy and long term toxicity.

Results: SBRT technique provided convenient precise approach in the management of primary as well as recurrent head and neck cancer with adequate local control rates and tolerable long term toxicity profile.

Conclusion: The use of stereotactic body radiotherapy is still evolving and multiple studies are needed to optimize the dose fractionation of SBRT and its integration with systemic therapy.

Read more here: http://www.eurekaselect.com/159256/article

MOST ACCESSED ARTICLE – Targeted Nanosystems for Cancer Therapy – Current Cancer Therapy Reviews

Journal: Current Cancer Therapy Reviews

Author(s): Ruhee Jain, Tahseen Khan, Sourabh Jain, Ashutosh Pal Jain, Aakanchha Jain

Graphical Abstract:

Abstract:

Background: Significant shortcomings have been displayed in conventional chemotherapeutics delivery which possesses some genuine side effects including harm of the immunity and different organs with quickly multiplying cells because of nonparticular focus on the absence of dissolvability and powerlessness to enter the tumor core bringing about debilitated treatment with diminished dosage and with low survival rate. Rapid development has adapted nanocarriers as distinct therapeutics which can directly access the tumor cells specifically with expanded medication limitation and cell take-up for cancer treatment.

Methodology: This review focuses on core objective of drug targeting to the cancerous cells by demonstrating the advantages of the young medical field, “nanocarriers” including liposomes, polymer based nanoparticles, metal based nanoparticles, dendrimers, protein linked systems, co-polymers and fullerenes, which have been proven remarkably promising in enhancing drug distribution and bioavailability, increasing half life and achieving targeted drug delivery, thus reducing toxicity.

Conclusion: Here we provide an update on the recent clinical trials in nanocarrier based therapy of colon rectal cancer, food and drug administration (FDA) approved nanomedicines for cancer and those in nanoplatforms which have reached an advanced stage of clinical development.

To access the article, please visit: http://www.eurekaselect.com/153540/article